AbbVie Presents New Lung Cancer Data at WCLC 2026
AbbVie will present new clinical data from its lung cancer pipeline at the World Conference on Lung Cancer (WCLC) 2026. The company will showcase results from its PD-1/VEGF bispecific antibody program and provide updates on other investigational therapies.
AbbVie is set to present new clinical data from its lung cancer pipeline at the World Conference on Lung Cancer (WCLC) 2026. The company's presentation will include data on ABBV-1480 (RC148), a PD-1/VEGF bispecific antibody, which is being investigated as a frontline treatment for non-small cell lung cancer (NSCLC).
The oral presentation of ABBV-1480 data highlights its potential as a new therapeutic option. Lung cancer remains a significant global health challenge, and the development of novel treatments is critical for improving patient outcomes. This bispecific antibody aims to target key pathways involved in tumor growth and immune evasion.
In addition to ABBV-1480, AbbVie will also provide updates and new data on its telisotuzumab adizutecan (Temab-A) and ABBV-706 programs. These presentations offer a comprehensive look at the company's ongoing efforts in advancing lung cancer research and development.
The company's participation in WCLC underscores its commitment to addressing the unmet needs in lung cancer treatment. By sharing its latest research findings, AbbVie aims to contribute to the scientific understanding and therapeutic landscape of lung cancer.